(Medical Xpress)—A team of researchers with members from Europe and the U.S. has found that viral replication may not be the main reason that the HIV virus is able to persist in the cells of infected patients for many years. ...
Clinical trial design for new cancer therapies has historically been focused on the tissue of origin of a tumor, but a paper from researchers at Memorial Sloan-Kettering Cancer Center published on September 26 in Nature Genetics ...
Sep 27, 2013
0
0
For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized gas - and chemo ...
May 23, 2013
1
0
Hailed as a major step forward in the effort to develop targeted cancer therapies, a recently approved drug for the most common type of skin cancer has been a mixed blessing for patients. Although the initial response is ...
Feb 27, 2013
0
0
A team of Spanish researchers say they have developed a therapeutic vaccine that can temporarily brake growth of the HIV virus in infected patients.
Jan 3, 2013
3
0
In the worldwide battle to curtail malaria, one of the most prevalent and deadly infectious diseases of the developing world, drug after drug has fallen by the wayside as the malaria parasite has become resistant to it. Only ...
Dec 20, 2012
1
0
(Medical Xpress)—A University of Arizona professor is overseeing the manufacture of an experimental drug that could help reduce brain damage after a stroke.
Sep 21, 2012
1
0
Researchers have demonstrated that a refined gene therapy approach safely restores the immune systems of some children with severe combined immunodeficiency (SCID). The rare condition blocks the normal development of a newborn's ...
Sep 11, 2012
0
0
(Medical Xpress) -- University of Florida researchers teamed with colleagues at City of Hope National Medical Center in Duarte, Calif., to devise a new combination therapy that reverses established Type 1 diabetes in mice.
May 10, 2012
0
0
A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated ...
Apr 16, 2024
0
26
